Page 2 - Glaxosmithkline Pharmaceuticals

Covid vaccines may become a viable business, but that's not good news

Vaccines are not consumer products made by pharmaceutical industry: they are infrastructure.

New launches to prop sales recovery as GSK Pharma gets over Zinetac pain

Near-term gains may be limited given restrictions which will impact anti-infectives portfolio

Drugmakers to hike prices for 2021 as Covid pressure puts revenues at risk

Drugmakers including Pfizer Inc, Sanofi SA, and GlaxoSmithKline Plc plan to raise US prices on more than 300 drugs in the United States on Jan 1

GlaxoSmithKline Pharma Q2 net profit declines 85% to Rs 76.47 crore

Drug firm GlaxoSmithKline Pharmaceuticals on Wednesday reported nearly 85 per cent decline in its consolidated net profit to Rs 76.47 crore for the quarter ended in September. The company had posted a net profit of Rs 502.75 crore for the corresponding period of the previous fiscal, it said in a BSE filing. Consolidated revenue from operations of the company stood at Rs 879.32 crore for the quarter under consideration. It was Rs 882.02 crore for the same period a year ago, it added. The company has recognised a financial impact of Rs 64.13 crore for the latest September quarter mainly to reflect the estimated realisable value of the assets, associated costs and impacts of reversal of provision on account of Zinetac recall, the filing said. The company had recognised an exceptional item of Rs 401.14 crore for the quarter ended September 30, 2019, it added. "GSK continues to demonstrate resilience in these times, as we focus our efforts on the safety of our employees while ensuring

Sanofi, GSK to supply up to 60 million doses of Covid-19 vaccine to UK

Sanofi and GSK said they had reached an agreement with Britain to supply it with up to 60 million doses of a potential Covid-19 vaccine, and that discussions with other governments were ongoing

Sanofi eyes Covid-19 vaccine approval in early 2021; partners Translate Bio

Many drugmakers are racing to come up with a safe and effective vaccine that can be produced at large scale

GlaxoSmithKline Q4 consolidated net profit declines 6% to Rs 138 cr

The company had posted a net profit of Rs 146.81 crore for the same period previous fiscal, GlaxoSmithKline Pharmaceuticals said in a BSE filing.

PPEs, work-life balance the new normal as pharma salesforce hits the field

GSK leads the charge with staggered return-to-work, others plans yoga sessions and health care webinars for salesperson's family

GSK to offload HUL stake worth Rs 26,000 cr in largest secondary sale

Over 133 million shares, or 5.7% of the paid-up capital, are being offered for Rs 1,850-1,950 to investors through a special block window

GlaxoSmithKline Pharma plunges 13% on net loss of Rs 661 crore in Q3

The company reported a consolidated net loss of Rs 661 crore for the quarter, mainly on account of financial impact related to the voluntary recall of Zinetac

GSK credits STEER for Horlicks technology after year-long IP battle

STEER which was founded in 1993 by Padmanabhan has 5 global offices and 10 satellite offices, serving over 39 countries. It employs over 500 engineers, scientists and technicians across the globe

From Celin to Septran, GSK Pharma sold 8-10 tail-end brands in FY19

The firm's FY19 annual report shows that it fetched Rs 5 crore during the year from the sale of brands

GlaxoSmithKline, Pfizer to combine consumer health businesses in JV

GSK said on Wednesday the deal laid the foundation for the creation of two new UK-based global companies focused on Pharmaceuticals/Vaccines and Consumer Healthcare

GSK Pharma to pare brands to 20 in India, bring new products into country

The company will launch brand extensions whenever needed and focus on bringing in patented product

GlaxoSmithKline Pharmaceuticals zooms 17% on 1:1 bonus

The stock surged 17% to Rs 3,249, also its 52-week high on the BSE, after its board recommended a bonus issue in the ratio of 1:1.

Cloud over GlaxoSmithKline deal affects outlook; stock down by 8.3%

Final value of transaction hinges on whether distribution arrangement is part of deal

GSK in pole position for Pfizer unit as Reckitt Benckiser quits auction

It is possible Pfizer may receive more offers, the sources added, or it could decide against a sale

GlaxoSmithKline, Reckitt Benckiser in final lap for Pfizer Inc's unit

Glaxo CEO Emma Walmsley said last month that the company's top priority is the pharmaceutical business

GlaxoSmithKline sets up first team for acquisitions in 93 years

As govt increasing price control over branded generic medicines has affected its profitability

GSK hires ex-Walmart executive to boost tech operations, digital platforms

Major drugmakers are grappling with the impact of technology on their businesses